Ascelia Pharma (Sweden) Insiders
| ACE Stock | SEK 3.07 0.15 4.66% |
Ascelia Pharma employs about 21 people. The company is managed by 6 executives with a total tenure of roughly 49 years, averaging almost 8.0 years of service per executive, having 3.5 employees per reported executive. Breaking down Ascelia Pharma's management performance can provide insight into the firm performance.
| Carl MD Insider Chief Officer |
| Julie Brogren Insider Deputy Officer |
Ascelia |
Ascelia Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.3347) % which means that it has lost $0.3347 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.537) %, meaning that it generated substantial loss on money invested by shareholders. Ascelia Pharma's management efficiency ratios could be used to measure how well Ascelia Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Ascelia Pharma Workforce Comparison
Ascelia Pharma AB is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 337. Ascelia Pharma holds roughly 21.0 in number of employees claiming about 6% of stocks in Biotechnology industry.
Ascelia Pharma AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Ascelia Pharma AB Price Series Summation is a cross summation of Ascelia Pharma price series and its benchmark/peer.
Ascelia Pharma Notable Stakeholders
An Ascelia Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ascelia Pharma often face trade-offs trying to please all of them. Ascelia Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ascelia Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Carl MD | Chief Officer | Profile | |
| Julie Brogren | Deputy Officer | Profile | |
| Magnus Corfitzen | Chief Officer | Profile | |
| Despina Hedin | Chief Officer | Profile | |
| Mikael Widell | Head Communications | Profile | |
| Andreas Norlin | Chief Officer | Profile |
About Ascelia Pharma Management Performance
The success or failure of an entity such as Ascelia Pharma AB often depends on how effective the management is. Ascelia Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ascelia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ascelia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Ascelia Pharma AB operates as an oncology focused specialty pharmaceutical company that develops medicines to enhance the life expectancy for people living with cancer and cancer-related diseases in Sweden and Denmark. The company was founded in 2000 and is headquartered in Malm, Sweden. Ascelia Pharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 4 people.
Please note, the imprecision that can be found in Ascelia Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ascelia Pharma AB. Check Ascelia Pharma's Beneish M Score to see the likelihood of Ascelia Pharma's management manipulating its earnings.
Ascelia Pharma Workforce Analysis
Traditionally, organizations such as Ascelia Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ascelia Pharma within its industry.Ascelia Pharma Manpower Efficiency
Return on Ascelia Pharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 6M | |
| Net Loss Per Executive | 21M |
Additional Tools for Ascelia Stock Analysis
When running Ascelia Pharma's price analysis, check to measure Ascelia Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascelia Pharma is operating at the current time. Most of Ascelia Pharma's value examination focuses on studying past and present price action to predict the probability of Ascelia Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascelia Pharma's price. Additionally, you may evaluate how the addition of Ascelia Pharma to your portfolios can decrease your overall portfolio volatility.